Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport.
GH abuse by elite athletes is currently undetectable. To define suitable markers of GH doping, we assessed the effects of acute exercise, GH administration, and GH withdrawal on the GH/insulin-like growth factor (IGF) axis in athletic adult males. Acute endurance-type exercise increased serum GH, GH-binding protein (GHBP), total IGF-I, IGF-binding protein (IGFBP)-3, and acid-labile subunit (ALS), each peaking at the end of exercise. IGFBP-1 increased after exercise was completed. Free IGF-I did not change with exercise. Recombinant human GH treatment (0.15 IU/kg x day) for 1 week increased serum total IGF-I, IGFBP-3, and ALS, exaggerating the responses to exercise. IGFBP-2 and IGFBP-1 were trivially suppressed. After GH withdrawal, the GH response to identical exercise was suppressed. Total IGF-I, IGFBP-3, and ALS returned to baseline over 3-4 days. In summary, 1) acute exercise transiently increased all components of the IGF-I ternary complex, possibly due to mobilization of preformed intact complexes; 2) GH pretreatment augmented the exercise-induced changes in ternary complexes; 3) postexercise IGFBP-1 increments may protect against delayed onset hypoglycemia; 4) serum total IGF-I, IGFBP-3, and ALS may be suitable markers of GH abuse; and 5) differences in disappearance times altered the sensitivity of each marker for detecting GH abuse.
Wallace
J D
JD
Metabolic Research Unit, Department of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia. jwallace@medicine.pa.uq.edu.au
Cuneo
R C
RC
Baxter
R
R
Orskov
H
H
Keay
N
N
Pentecost
C
C
Dall
R
R
Rosén
T
T
Jørgensen
J O
JO
Cittadini
A
A
Longobardi
S
S
Sacca
L
L
Christiansen
J S
JS
Bengtsson
B A
BA
Sönksen
P H
PH
D000328:Adult; D002352:Carrier Proteins / Q000097:blood; D015444:Exercise; D006023:Glycoproteins / Q000097:blood; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000097:blood* / Q000494:pharmacology*; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D007700:Kinetics; D008297:Male; D010806:Physical Education and Training; D010807:Physical Endurance; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D013002:Somatomedins / Q000032:analysis*; D013178:Sports Medicine / Q000379:methods; D019966:Substance-Related Disorders / Q000175:diagnosis; D013997:Time Factors
D002352:Carrier Proteins; D006023:Glycoproteins; D018972:Insulin-Like Growth Factor Binding Protein 3; D011994:Recombinant Proteins; D013002:Somatomedins; C075944:insulin-like growth factor binding protein, acid labile subunit; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I